TVTX
Travere Therapeutics, Inc.
A biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is FDA-approved to slow kidney function decline in adults with a rare kidney disease called primary IgA nephropathy, and the company also sells Thiola and Thiola EC for the kidney stone condition cystinuria. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for the rare metabolic disorder classical HCU.
CUSIP: 89422G107HealthcareUS1 holder
Total Value
$1.95M
Total Shares
34.3K
Net Share Change
+34.3K
Activity
1 buying
Investor
Value
Shares
Weight
Change
